CY1120050T1 - Φαρμακοτεχνικες μορφες για την αποδεσμευση δραστικων ενωσεων - Google Patents

Φαρμακοτεχνικες μορφες για την αποδεσμευση δραστικων ενωσεων

Info

Publication number
CY1120050T1
CY1120050T1 CY20181100045T CY181100045T CY1120050T1 CY 1120050 T1 CY1120050 T1 CY 1120050T1 CY 20181100045 T CY20181100045 T CY 20181100045T CY 181100045 T CY181100045 T CY 181100045T CY 1120050 T1 CY1120050 T1 CY 1120050T1
Authority
CY
Cyprus
Prior art keywords
formulation
removal
active compounds
pharmaceutical forms
glycosaminoglycan
Prior art date
Application number
CY20181100045T
Other languages
English (en)
Inventor
Guillermo Franco Rodríguez
Ibón Gutierro Aduriz
Original Assignee
Laboratorios Farmacéuticos Rovi, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Farmacéuticos Rovi, S.A. filed Critical Laboratorios Farmacéuticos Rovi, S.A.
Publication of CY1120050T1 publication Critical patent/CY1120050T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Φαρμακοτεχνική μορφή που περιλαμβάνει μια γλυκοζαμινογλυκάνη και μια ένωση που διαθέτει ανεξάρτητες ή εξαρτημένες από το pΗ ομάδες τεταρτοταγούς αμμωνίου, όπου η αναλογία των ομάδων αμμωνίου στη φαρμακοτεχνική μορφή κυμαίνεται μεταξύ 0,01 και 2,0 μmοΙ αμμωνίου/mg της φαρμακοτεχνικής μορφής, η αναλογία της γλυκοζαμινογλυκάνης στη φαρμακοτεχνική μορφή κυμαίνεται μεταξύ 15% και 50% κατά βάρος και η φαρμακοτεχνική μορφή διαθέτει ποσοστό υγρασίας (κατά βάρος) κάτω του 10%. Φαρμακευτικό σκεύασμα που περιλαμβάνει την εν λόγω φαρμακοτεχνική μορφή και η χρήση τους για την παραγωγή ενός φαρμάκου.
CY20181100045T 2009-01-30 2018-01-16 Φαρμακοτεχνικες μορφες για την αποδεσμευση δραστικων ενωσεων CY1120050T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382014A EP2213282A1 (en) 2009-01-30 2009-01-30 Pharmaceutical forms for the release of active compounds
PCT/EP2010/051127 WO2010086425A1 (en) 2009-01-30 2010-01-29 Pharmaceutical forms for the release of active compounds
EP10702287.3A EP2391352B1 (en) 2009-01-30 2010-01-29 Pharmaceutical forms for the release of active compounds

Publications (1)

Publication Number Publication Date
CY1120050T1 true CY1120050T1 (el) 2018-12-12

Family

ID=40602343

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100045T CY1120050T1 (el) 2009-01-30 2018-01-16 Φαρμακοτεχνικες μορφες για την αποδεσμευση δραστικων ενωσεων

Country Status (11)

Country Link
EP (2) EP2213282A1 (el)
CY (1) CY1120050T1 (el)
DK (1) DK2391352T3 (el)
ES (1) ES2655689T3 (el)
HR (1) HRP20180103T1 (el)
HU (1) HUE037915T2 (el)
LT (1) LT2391352T (el)
PL (1) PL2391352T3 (el)
PT (1) PT2391352T (el)
SI (1) SI2391352T1 (el)
WO (2) WO2010086425A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102120781B (zh) * 2011-03-16 2013-07-17 中国药科大学 一种新型胰岛素口服纳米粒的制备及应用
EP3451730B1 (en) 2011-04-01 2024-03-27 Mitsubishi Electric Corporation User equipment performing radio communication and base station used in a communication system
EP3273239A1 (en) 2016-07-19 2018-01-24 Laboratorios Farmacéuticos Rovi, S.A. Procedure of analysis of glycosaminoglycans, heparins and their derivatives by nuclear magnetic resonance

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3482014A (en) 1966-06-29 1969-12-02 Canada Packers Ltd Orally active heparin and method for making and using same
US4703042A (en) 1984-05-21 1987-10-27 Bodor Nicholas S Orally active heparin salts containing multivalent cationic units
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
FR2811227A1 (fr) * 2000-07-07 2002-01-11 Philippe Maincent Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
ITMI20012599A1 (it) 2001-12-11 2003-06-11 Cosmo Spa Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int
KR100508911B1 (ko) * 2002-05-09 2005-08-18 주식회사 펩트론 서방성 단백질 약물 제형 및 이의 제조방법
GB0310919D0 (en) * 2003-05-13 2003-06-18 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
ES2222822B1 (es) 2003-07-28 2005-12-16 Laboratorios Farmaceuticos Rovi, S.A. Diamidas de aminoacidos en posicion no alfa utiles como adyuvantes para la administracion de agentes biologicos activos.
BRPI0414982A (pt) * 2003-10-01 2006-11-21 Debio Rech Pharma Sa dispositivo e método para produção de partìculas
US7556826B2 (en) * 2005-01-04 2009-07-07 Gp Medical, Inc. Nanoparticles for protein drug delivery
US20070154546A1 (en) 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
ES2296529B1 (es) 2006-08-07 2009-04-01 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con promotores de absorcion.

Also Published As

Publication number Publication date
HRP20180103T1 (hr) 2018-04-20
EP2213282A1 (en) 2010-08-04
WO2010086425A1 (en) 2010-08-05
PL2391352T3 (pl) 2018-05-30
HUE037915T2 (hu) 2018-09-28
PT2391352T (pt) 2018-01-19
ES2655689T3 (es) 2018-02-21
LT2391352T (lt) 2018-05-25
EP2391352B1 (en) 2017-11-01
WO2010086427A1 (en) 2010-08-05
EP2391352A1 (en) 2011-12-07
DK2391352T3 (da) 2018-01-29
SI2391352T1 (en) 2018-04-30

Similar Documents

Publication Publication Date Title
CL2020000468A1 (es) Uso de una formulación estable que comprende una enzima de reemplazo para la enzima lisosomal (divisional solicitud 201801220)
EA201101192A1 (ru) Фармацевтическая композиция, включающая производные глюкопиранозилдифенилметана, фармацевтическая дозированная форма, содержащая указанные производные, способ их получения и применения для улучшения гликемического контроля у пациентов
EA201170772A1 (ru) Органические соединения
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201070597A1 (ru) Антибактериальные аналоги аминогликозида
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201791850A1 (ru) Борсодержащие малые молекулы
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
EA201400311A1 (ru) Аминозамещенные имидазопиридазины
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0821004A8 (pt) Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
NO20075111L (no) Farmasoytisk sammensetning
MA32776B1 (fr) Inhibiteurs de l'akt et de la p70 s6 kinase
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
TR200806298A2 (tr) Farmasötik formülasyon
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
CY1120050T1 (el) Φαρμακοτεχνικες μορφες για την αποδεσμευση δραστικων ενωσεων